Regulatory & Policy

FDA Approves ACCRUFeR by Shield Therapeutics as First Prescription Oral Iron for Pediatric Iron Deficiency

The US FDA has approved ACCRUFeR (ferric maltol) for the treatment of iron deficiency in children aged 10 years and older, Shield Therapeutics announced on...

Edited by Robert McTiernan··5 min read

US FDA Grants ACCRUFeR Pediatric Approval, Establishing First Prescription Oral Iron for Children

The US FDA has approved ACCRUFeR (ferric maltol) for the treatment of iron deficiency in children aged 10 years and older, Shield Therapeutics announced on 17 February 2026. The ACCRUFeR FDA approval marks the first time a prescription oral iron therapy has received regulatory clearance specifically for a pediatric population in the United States. The drug has been available to adults with iron deficiency since its initial US approval in 2019. Shield Therapeutics, a London-headquartered specialty pharmaceutical company, developed and holds the rights to ferric maltol, which is also marketed as FeRACCRU in other territories.

Dosing and Regulatory Pathway

ACCRUFeR is a non-salt-based oral iron formulation administered twice daily. The company describes the product as a stable complex of ferric iron with maltol, a naturally occurring sugar derivative. For the pediatric expansion, the drug is indicated for patients aged 10 and older with iron deficiency. The US FDA announcement characterized the approval as the first prescription oral medicine for iron deficiency in this age group. Full prescribing information, including dosing specifics for the pediatric population, is available through the product's label page. The regulatory pathway details — including whether the pediatric indication received priority review or any other expedited designation — were not specified in the company's announcement.

Clinical Evidence Supporting the Pediatric Label

The pediatric approval was supported by the FORTIS study (NCT05126901), a Phase 3 trial evaluating ferric maltol oral suspension against ferrous sulfate liquid in children and adolescents with iron deficiency. The study assessed the effect of 12 weeks of twice-daily ferric maltol on hemoglobin concentration and iron markers, with safety and gastrointestinal tolerability serving as co-primary objectives. Shield Therapeutics reported positive results from the trial, though the company's press release did not disclose specific effect sizes, responder rates, or statistical comparisons. A separate Phase 1 pharmacokinetic crossover study (NCT04626414) compared ferric maltol capsule and oral suspension formulations in healthy adult volunteers under fed and fasted conditions, providing bridging data for the liquid formulation intended for younger patients. The company's announcement noted that ACCRUFeR was "designed with tolerability in mind," referencing the gastrointestinal side effects — stomach upset, nausea, and constipation — that commonly limit adherence to conventional iron supplements in children. Detailed adverse event rates from the FORTIS trial have not been publicly disclosed in the materials reviewed.

Iron Deficiency in Children and the Rationale for a Prescription Oral Iron

Iron deficiency affects approximately 2.4 million children in the United States, according to figures cited in Shield Therapeutics' announcement. Adolescent females face a disproportionate burden: up to 40% of those aged 12 to 21 may be affected, driven by menstrual blood loss and increased iron requirements during puberty. Other risk factors include dietary insufficiency, high-intensity athletic training, obesity, and rapid growth. Left untreated, iron deficiency in children can contribute to developmental delays, reduced academic performance, behavioral changes, and weakened immune function.

The standard approach to pediatric iron deficiency has historically relied on over-the-counter ferrous salt preparations — ferrous sulfate, ferrous gluconate, and ferrous fumarate — which are widely available and inexpensive. However, these formulations are associated with a well-documented burden of gastrointestinal side effects that frequently compromise adherence, particularly in younger patients. Ferric maltol differs from conventional ferrous salts in that it delivers iron in the ferric (Fe³⁺) state complexed with maltol, which the company describes as conferring a distinct absorption mechanism compared to salt-based preparations. The precise molecular pathway — including the roles of intestinal transporters such as DMT1 and ferroportin — is not detailed in the company's public materials, though the functional objective is the same: restoring systemic iron stores through oral supplementation. The prescription oral iron pediatric space has, until this approval, lacked a product with a formal FDA-cleared indication for children, meaning that clinicians treating iron deficiency in this age group were relying on products without pediatric-specific labeling or evidence packages.

The AllSci BriefSystematic R&D and deal news. Daily.

Shield Therapeutics developed ferric maltol internally and has managed its regulatory and commercial trajectory across multiple markets. The molecule received European marketing authorization before its 2019 US adult approval. The company has not disclosed acquisition or in-licensing arrangements related to the molecule's origin. Beyond iron deficiency as a standalone condition, ferric maltol has been studied in adult populations with iron deficiency anemia associated with inflammatory bowel disease and chronic kidney disease, though the current pediatric label is specific to iron deficiency regardless of underlying cause.

The Competitive and Development Landscape for Iron Deficiency Treatment in Children

The prescription iron deficiency treatment children receive today is shaped more by formulation innovation and dosing strategy than by novel biological targets. No other prescription oral iron product currently holds a pediatric-specific FDA indication, which is the central differentiating claim in Shield Therapeutics' announcement. Intravenous iron formulations — including ferric carboxymaltose (Injectafer, Daiichi Sankyo) and iron sucrose (Venofer, American Regent) — are used in select pediatric cases, particularly when oral therapy fails or is contraindicated, but these carry the logistical burden of infusion visits and are not directly comparable in positioning to an oral product.

In terms of clinical development activity indexed to this indication, the pipeline for pediatric iron deficiency remains narrow. The FORTIS trial and the associated Phase 1 PK study represent the only clearly indexed development programs with completed pediatric data packages in the available trial databases. A Phase II trial evaluating a nano-iron supplement in young children aged 6 to 35 months (the IHAT-GUT study) has explored whether engineered iron nanoparticles can reduce the gut microbiome disruption associated with conventional iron salts, though this program targets a younger age group and a different formulation strategy. Recent reviews of pediatric iron therapy have emphasized dosing optimization — including alternate-day regimens and lower individual doses — as a pragmatic approach to improving tolerability with existing formulations, rather than introducing new molecular entities.

The ACCRUFeR FDA approval adds to a clinical environment where the primary unmet need is not the absence of iron itself but the difficulty of delivering it in a form that pediatric patients will tolerate consistently over a treatment course lasting weeks to months. Whether ferric maltol's tolerability profile translates into measurably better adherence and clinical outcomes relative to ferrous sulfate in real-world pediatric practice remains to be established through post-marketing data and independent comparative studies.

Spot something wrong? Report an issue with this article